<DOC>
	<DOCNO>NCT01088893</DOCNO>
	<brief_summary>This randomize control pilot study investigate signal involve drug resistance chemotherapy . Patient randomize undergo observation receive Everolimus completion neoadjvuant treatment ( anthracycline and/or taxane-based ) surgery . The patient monitor efficacy safety .</brief_summary>
	<brief_title>Everolimus Breast Cancer Patients After Pre-operative Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Women age ≥ 18 year ; Histologically and/or cytologically confirm invasive ductal lobular breast cancer ; Tumor 3 cm great time diagnosis Measurable primary tumor neoadjuvant treatment randomization No prior chemotherapy breast cancer ; ECOG performance status ≤1 Karnofsky performace status ≥ 70 % Adequate liver/renal function Able swallow whole tablet . Able give write informed consent Able follow prescription instruction reasonably well Male patient Prior history malignancy within 5 year study entry , aside contralateral breast carcinoma , appropriately treated cervical carcinoma situ , adequately treat basal squamous cell carcinoma skin Distant metastasis , include skin involvement beyond breast area Other severe acute chronic medical psychiatric condition , laboratory abnormality would impart , judgment investigator , excess risk associate study participation study drug administration , , judgment investigator , would make patient inappropriate entry study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>everolimus</keyword>
	<keyword>neoadjuvant</keyword>
	<keyword>m-TOR inhibitor</keyword>
</DOC>